+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

  • ID: 4701807
  • Drug Pipelines
  • 32 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Janssen
  • Lilly
  • Pfizer
  • Takeda
  • MORE
Summary

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics -
  • Perception of Phase II mirikizumab induction data in UC
  • Perception of mirikizumab’s Phase III study in UC
  • Future expectations of mirikizumab in UC
  • Future expectations for mirikizumab in Crohn’s disease
Key Highlights
  • All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
  • Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab’s ongoing Phase III UC trial
  • KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during July 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Janssen
  • Lilly
  • Pfizer
  • Takeda
  • MORE
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Lilly
  • Takeda
  • Pfizer
  • Janssen
Note: Product cover images may vary from those shown
Adroll
adroll